Compare Ascendis Pharma A/S (ASND) vs Dow Inc (DOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Dow Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Dow Inc trades at $29.31 (market cap $20.92B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays a 4.82% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DOW | |
|---|---|---|
Market Cap | $17.74B | $20.92B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $41.87 |
52-Week Low | $163.32 | $20.65 |
Enterprise Value | $18.11B | $36.70B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DOW trades at $29.03, up 1.86% today, but remains in a bearish technical trend with support near $28. The company reported a net loss of $2.62 billion in 2025, with negative profit margins and declining revenue, though it has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $36.11 price target, indicating potential upside if fundamentals improve.
The outlook is cautious; while liquidity supports dividends and the stock trades below book value, persistent losses and high debt pose significant risks. Investor sentiment is mixed amid broader market volatility, with earnings performance being the critical factor for any sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
